Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

Biologics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

The global biologics market size reached US$ 321.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 535.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.1% during 2023-2028.

Biologics, also known as biological drugs, are disease-modifying antirheumatic drugs (DMARDs) made from living organisms or consist of components of living organisms. They include a wide variety of products, such as vaccines, blood, blood components, cells, genes, tissues, allergens, and recombinant proteins, derived from humans, animals, birds, insects, plants, and microorganisms. These products control the production of vital proteins, modify human hormones and cells, while producing substances to activate and suppress the immune system. They also change the manner of operation of natural biologic intracellular and cellular actions. In recent years, biologics have gained immense traction as they are essentially utilized to treat various diseases and conditions, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis and other autoimmune diseases.

Biologics Market Trends:
The global biologics market is primarily driven by the rising incidences and diagnosis of chronic diseases that have necessitated the availability of advanced diagnostics and treatment drugs. Biologics are genetically engineered to target a specific part of the immune system that fuels inflammation. Governments of different countries are also taking initiatives to promote the healthcare sector and ensure the availability of biologics with the onset of coronavirus disease (COVID-19). Furthermore, scientists and researchers are extensively investigating species and expression systems to enhance the productivity of biological products. Moreover, various pharmaceutical companies are undertaking research and development (R&D) activities to improve the efficacy of oral products for rheumatoid arthritis and Crohn’s diseases.

Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global biologics market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on source, product, disease and manufacturing.

Breakup by Source:Microbial
Mammalian
Others

Breakup by Product:

Monoclonal Antibodies
Vaccines
Recombinant Proteins
Antisense, RNAi and Molecular Therapy
Others

Breakup by Disease:

Oncology
Immunological Disorders
Cardiovascular Disorders
Hematological Disorders
Others

Breakup by Manufacturing:

Outsourced
In-House

Breakup by Region:

North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., AstraZeneca plc, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Johnson & Johnson, Merck KGaA, Novartis AG, Pfizer Inc. and Sanofi.

Key Questions Answered in This Report

1. What was the size of the global biologics market in 2022?
2. What is the expected growth rate of the global biologics market during 2023-2028?
3. What are the key factors driving the global biologics market?
4. What has been the impact of COVID-19 on the global biologics market?
5. What is the breakup of the global biologics market based on the source?
6. What is the breakup of the global biologics market based on the product?
7. What is the breakup of the global biologics market based on the disease?
8. What is the breakup of the global biologics market based on the manufacturing?
9. What are the key regions in the global biologics market?
10. Who are the key players/companies in the global biologics market?